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(57) ABSTRACT 
A method and a test for using carbonic anhydrase (CA), 
particularly CA-I or CA-II, as a biomarker ofhemolysis. The 
method and test detect hemolysis by determining a percent-
age erythrocyte hemolysis in a specimen or sample of blood 
based upon quantification of carbonic anhydrase present in 
the extracellular portion of the blood. The method and test 
serve to optimize therapeutic efficacy for treatments of 
hemolysis. Plasma carbonic anhydrase is used to determine 
the percentage hemolysis in plasma. Furthermore, CA is 
quantified with specificity to the isozyme present in the 
plasma. 
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Figure 1. Standard curve for CA-I purchased from 
Sigma 
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FIGURE2 
Figure 2. Monoclonal Ab ELISA to detect CA-I in human 
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plasma containing known amount of hemolysate 
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FIGURE3A 
Standard curve 
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FIGURE3B 
Human Plasma compared to CAI standard curve 
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METHOD OF USING CARBONIC 
ANHYDRASE TO DETECT HEMOLYSIS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
[0001] This application claims the benefit of U.S. Provi-
sional Patent Application No. 61/281,998, filed Nov. 25, 
2009, herein incorporated by reference. 
FIELD OF THE INVENTION 
[0002] The present invention relates to a method and a test 
to detect erythrocyte hemolysis using carbonic anhydrase, 
more particularly carbonic anhydrase I or II. 
BACKGROUND OF THE INVENTION 
[0003] Carbonic anhydrase (CA) represents the second 
most abundant protein present inside the erythrocytes. With 
the exception of the hagfish and other lampreys, carbonic 
anhydrase activity or content is normally extremely low in 
vertebrates in the plasma. Carbonic anhydrase exists in at 
least twelve different isozymes, with variable distribution 
among tissues. The CA-I and CA-II isozymes predominate in 
erythrocytes, with a small amount of CA-III. Isozymes CA-
IV to XII are found in many other tissues, including the gut, 
kidney and lung. Indeed, CA-IX is under study as a potential 
biomarker ofrenal and squamous cell carcinoma. 
[0004] However, the characteristics and fate of free CA in 
plasma are poorly understood. Roush and Fiercke reported 
that free CA-I, CA-II, and CA-III in plasma is rapidly bound 
and inactivated by a transferrin-like protein, followed by 
clearance in the reticuloendothelial system. Studies of radio-
labelled CA in rats demonstrates an approximate half-life of 
two hours with elimination in the kidney and liver for CA 
isozymes I and II. 
[0005] It is known to those skilled in the art that the activity 
of carbonic anhydrase can be measured by colorimetric 
assays, typically employing a substrate that is recognized and 
cleaved by the active site of CA. One such example is the 
compound para nitro phenylacetate. Since carbonic anhy-
drase has intrinsic esterase activity, it will cleave the dye 
(p-nitrophenol) from the acetate liberating a color in aqueous 
solution that can be assayed by standard colorimetric tech-
niques. However, such a method has multiple limitations. 
First, the plasma of mammals contains other esterases that 
will hydrolyze the substrate molecule and liberate the dye 
(example given, acetyl cholinesterase), this enzyme assay 
liberates very non-specific results. Other problems with the 
enzymatic assay include the fact that CA is inhibited by 
circulating proteins, as well as drugs, including sulfanilim-
ides, ethanol and morphine. 
[0006] Existing methods used to detect hemolysis have 
many shortcomings, most notably the inability to accurately 
quantify the percentage of erythrocytes hemolyzed based on 
a sample volume basis. 
[0007] Existing methods indirectly point toward presence 
ofhemolysis by measuring the disappearance plasma hapto-
globin or appearance of bilirubin, a product of enzymatic 
oxidation of the heme moiety of hemoglobin by the enzyme 
hemeoxygenase. Erythrocyte destruction results in the 
release free hemoglobin, the most abundant protein in red 
blood cells, into the plasma. Free hemoglobin is rapidly and 
avidly bound by the circulating protein haptoglobin and to a 
lesser extent, hemopexin. The haptoglobin-hemoglobin is 
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then bound to the scavenger receptor, CD-163, present on 
macrophages, monocytes, liver and spleen, and is removed 
from the circulation. As a result, the haptoglobin decreases in 
the presence ofhemolysis. The limitations ofhaptoglobin are 
that a clinician can only know if the haptoglobin is lower than 
normal, and the clinician is almost never aware of the 
patient's baseline haptoglobin concentration. Moreover, hap-
toglobin synthesis is induced by many inflammatory condi-
tions, including infection, cancer and drugs-the very stimuli 
that can actually produce hemolysis, such that a normal hap-
toglobin concentration can occur even with significant 
hemolysis. Thus, haptoglobin provides limited information 
about the degree ofhemolysis. 
[0008] It is well recognized that free plasma hemoglobin 
can be detected by spectrophotometric methods as well as 
immunoassay. However, because free hemoglobin is rapidly 
bound to haptoglobin and removed, it is not a reliable mea-
surement ofhemolysis produced by disease. Similarly, potas-
sium is released from erythrocytes, but it is rapidly equili-
brated within other cells of the body and therefore cannot be 
used to quantify the percentage hemolysis. Measurement of 
elevated plasma concentrations of unconjugated bilirubin and 
other products of the Heme oxygenase enzyme pathway also 
indicate evidence ofhemolysis. However, the production of 
bilirubin from hemolysis varies depending upon the amount 
and activity of the heme oxygenase enzyme. Because heme 
oxygenase is highly inducible, and dependent upon certain 
genotypes, its activity cannot be predicted. The rate of elimi-
nation of unconjugated bilirubin is also difficult to predict 
because this depends upon hepatic function, blood flow and 
nutritional status. This, bilirubin does not suffice to quantify 
the degree ofhemolysis. 
[0009] Accordingly, there is a need for a test and for a 
method to detect hemolysis and to optimize therapeutic effi-
cacy that overcomes the disadvantages discussed herein. 
SUMMARY OF THE INVENTION 
[0010] The present invention is directed to a method and a 
test forusing carbonic anhydrase, particularly CA-I or CA-II, 
as a biomarker of hemolysis. Thus, the present invention 
relates to a method and to a test for detecting hemolysis by 
determining a percentage erythrocyte hemolysis in a speci-
men or sample of blood based upon quantification of carbonic 
anhydrase (CA) present in the extracellular portion of the 
blood. The method and test serve to optimize therapeutic 
efficacy for treatments ofhemolysis. Plasma carbonic anhy-
drase is used to determine the percentage hemolysis in 
plasma. Furthermore, for the purpose of this invention, CA is 
quantified with specificity to the isozyme present in the 
plasma. 
[0011] It is within the scope of the present invention to 
provide a test or an assay that results in a color change that can 
be optically measured and the result converted from a nomo-
gram or formula into a percentage hemolysis in a sample. This 
percentage can be used to optimize the efficacy of treatments 
for hemolysis. This percentage can be understood by the 
following hypothetical consideration. Consider a tube of 99 
mL of plasma, completely devoid of any volume of erythro-
cytes. Thus, tube has 0% hemolysis. A second tube of 1 mL of 
packed red blood cells (PRBCs), which are for all practical 
purposes 100% erythrocytes by volume. If the second tube is 
subjected to high energy sonication, the erythrocytes will 
rupture, and the tube will contain 100% hemolysate. If 1 mL 
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of this hemolysate is added to tube 1, then tube 1 would then 
contain 1 % hemolysis by volume. 
[0012] The significance of a test to quantify the percentage 
of hemolysis in a sample would have applicability to many 
diseases. These include genetic hemoglobinopathies, inher-
ited abnormalities of the erythrocyte, including spherocyto-
sis, paroxysmal nocturnal hemoglobinuria, thalassemias, dis-
seminated intravascular coagulation secondary to infection, 
trauma, or cancer, erythrocyte destruction secondary to 
immune response to drugs, viral infections, and other stimuli, 
erythrocyte destruction secondary intravascular devices such 
as heart valves or from pulmonary hypertension. 
[0013] Further areas of applicability of the present inven-
tion will become apparent from the detailed description pro-
vided hereinafter. It should be understood that the detailed 
description and specific examples, while indicating the pre-
ferred embodiment of the invention, are intended for purposes 
of illustration only and are not intended to limit the scope of 
the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0014] The present invention will become more fully 
understood from the detailed description and the accompa-
nying drawings, which are not necessarily to scale, wherein: 
[0015] FIG. 1 is a graph of a standard curve for CA-1 
illustrating CA-1 protein concentration (ng/well) versus opti-
cal density (OD) value at 450 nm. 
[0016] FIG. 2 is a graph of a monoclonal Ab ELISA to 
detect CA-1 in human plasma containing a known amount of 
hemolysate illustrating percent (%) hemolysis versus optical 
density (OD) at 450 nm. FIG. 2 illustrates the nomogram 
principle wherein the degree of color change corresponds to 
the percentage ofhemolyzed cells in a sample. 
[0017] FIGS. 3A and 3B illustrate plots of two sets of data 
as set forth in Example 5. 
DETAILED DESCRIPTION OF THE INVENTION 
[0018] The following detailed description of the embodi-
ment(s) is merely exemplary in nature and is in no way 
intended to limit the invention, its application, or uses. 
[0019] A blood sample is obtained from a subject with 
minimal iatrogenic hemolysis. Accordingly, it is advisable 
that the blood sample should be taken from as large bore an IV 
as possible, preferably 18 gauge or larger. Moreover, the 
blood sample is centrifuged to separate the erythrocyte from 
the plasma or serum component. Further, this serum or 
plasma component can be assayed for its potassium concen-
tration, and ifthe potassium concentration is above 5.5 mEq/ 
L, this could be strongly suggestive of erythrocyte destruction 
that occurred during the venipuncture and blood handling 
process. Specimens with serum or plasma potassium concen-
tration above 5.5 mEq/L should be interpreted with caution or 
should be discarded. 
[0020] Since the carbonic anhydrase enzyme exists in mul-
tiple isoenzymes that are produced by different tissues, it is 
important in accordance with the present invention to focus 
on carbonic anhydrase that is present in the erythrocytes. 
[ 0021] One method of overcoming the limitations ofknown 
enzyme assays is to employ an antibody derived from a mono-
clonal cell line with a Fab portion that specifically recognizes 
the amino acid sequence unique to either carbonic anhydrase 
isoenzyme I or isoenzyme II, and to perform a standard 
enzyme-linked immunosorbent assay (ELISA). 
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[0022] In accordance with the present invention, the 
method of the present invention determines the percentage 
hemolysis in plasma by quantifying the amount of carbonic 
anhydrase I activity. The method generally comprises the 
following method steps. A blood sample is obtained from a 
subject, preferably a human subject having minimal iatro-
genic hemolysis. The blood sample is centrifuged to separate 
erythrocyte from the plasma or serum component of the 
blood. An anti carbonic anhydrase I antibody or molecule 
similarly capable of specific binding to carbonic anhydrase 
such as a DNA aptamer, is immobilized on a durable surface 
including glass, plastic, polycarbonate, or other material to 
allow secondary optical interogation. Examples of this immo-
bile surface include the bottom of a well in a microplate 
commonly used for ELISA detection of analytes or an immo-
bilation platform to allow reflection absoprtiometry or fluo-
rometric detection (e.g., the Luminex® detection system). 
Alternatively, the concentration could be determined by 
analysis of the spectra produced by bombarding a portion of 
the plasma with a beam of electrons and using mass spec-
trometry to analyze the ionized peptide fragments (see 
example table set forth herein demonstrating the results of 
plasma from rats with experimental pulmonary embolism). 
The plasma fraction, separated by centrifugation of a speci-
men of blood is added to a vessel that contains the surface 
with the immobilized antibody. A polyclonal antibody, or 
similar capture molecule, directed against carbonic anhy-
drase I containing a biotin label or other fluorescent, colori-
metric or chemical property is added to the vessel. The optical 
density is measured at the appropriate wavelengths depend-
ing upon the absorption spectrum of the detection label. Alter-
natively, carbonic anhydrase could be determined by mass-
based methods including altered resonance properties caused 
by antibody-capture of carbonic anhydrase on a piezoelectric 
material. Alternatively, carbonic anhydrase could be detected 
by reflection absorptiometry accomplished by measuring the 
change in an optical transmissive or reflective property con-
ferred by the direct binding of carbonic anhydrase to a cap-
turing molecule bound to an immobile surface. 
[0023] The optical density is plotted on a nomogram or 
nomograph. Alternatively, the optical density is calculated 
using an equation to estimate the percent hemolysis present in 
the plasma fraction or component. The calculation may be 
automated, for example, using a computer or other device to 
run a computerized analysis. 
[0024] The method further comprises converting the 
amount of carbonic anhydrase activity into a percentage 
hemolysis in the plasma fraction using the nomogram or the 
equation. 
[0025] The percentage of erythrocytes hemolyzed is deter-
mined by measuring the percentage hematocrit in a noncen-
trifuged blood specimen and employing an equation or for-
mula containing the variables hematocrit and percentage 
hemolysis. 
[0026] The percentage hemolysis is used to diagnose and 
monitor diseases and conditions that produce intravascular 
hemolysis as well as to optimize the therapeutic efficacy of 
treatment for hemolysis. Carbonic anhydrase (CA isoforms I 
and II), exists in high concentrations in erythrocytes, but not 
in plasma. In accordance with the present invention, it was 
determined that the method of the present invention uses the 
CA present in plasma as a quantitative biological indicator of 
intravascular hemolysis. 
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[0027] The present invention also relates to a test or kit for 
the detection ofhemolysis up to about at least about 5 to 6%. 
This is a very important range clinically because, for 
example, at concentrations such as 8 to 10% the plasma 
begins to tum pink which is a visible indicator of free hemo-
globin. The test or kit of the present invention is useful to 
identify patients with chronic diseases who are susceptible to 
hemolysis, and possibly to discover it earlier. For example, 
the test or kit could be used for various medical applications 
including, but not limited to, monitor patients on drugs that 
predispose to hemolysis as well as patients with hemoglo-
binopathies, patients at risk for disseminated intravascular 
coagulation, monitor malaria, assess severity of pulmonary 
hypertension, and for the initial work-up for anemia. 
[0028] The present invention also relates to a method of 
diagnosing or treating a patient. The method comprises 
obtaining a percentage ofhemolysis from a nomogram com-
prising a first set of data corresponding to optical density of a 
plasma component of a blood sample obtained from a subject 
and a second set of data corresponding to carbonic anhydrase 
I activity. The first set of data and the second set of data are 
plotted to form a graphical measure or an equation used to 
determine the percentage of hemolysis in the sample. The 
obtained percentage of hemolysis is used to diagnose or to 
treat the patient. For example, in the case of treatment by 
dosage of medication, a value of 0% hemolysis indicates a 
zero dosage amount, a value above 5% hemolysis indicates 
full dosage, and a value between 0 and 5% hemolysis indicate 
partial dosage, determined in proportion to the percentage of 
hemolysis obtained. 
Example 1 
[0029] Standard solutions for analysis were prepared as 
follows. The percentage hemolysis was determined experi-
mentally by carefully drawing a blood sample from a human 
that produced no hemolysis during phlebotomy portion. The 
sample was centrifuged at 3500xg for 10 min at 0° C. The 
plasma fraction with no hemolysis was removed and the 
hemolysate was produced from the packed red blood cells 
(PRBC) fraction by combining 0.5 mL of PRBCs with 0.75 
mL of distilled water followed by sonication for 4 minutes. 
The resultant mixture was assumed to contain 40% hemoly-
sate, and was then centrifuged and combined with neat 
plasma to produce known 0%, 0.1 %, 2.5%, 5%, and 10% 
hemolysate. A standard curve was based upon purchased 
human CA-1 protein (Sigma C-4396) dissolved in distilled 
water. 
[0030] In initial experiments, a polyclonal anti-CA anti-
body was tested and found extremely high background color 
change in plasma containing 0% hemolysate, indicating non-
specific binding, and compelling the need for a monoclonal 
antibody directed against CA-1. 
Example 2 
[0031] An experiment was conducted in accordance with 
the present invention using a purchased monoclonal antibody 
against carbonic anhydrase isoenzyme I (CA-I) in humans. 
The antibody was purchased from a commercial source (Ab-
eam). This monoclonal, anti human CA-I antibody repre-
sented the capturing antibody. A 1: 10,000 dilution of the 
monoclonal anti-CA I antibody was incubated in a phos-
phate-containing buffer for sufficient time to allow binding to 
the bottom of the wells of a standard 96-well micro plate. This 
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antibody served as the CA-I capture antibody. In the next step, 
human plasma was introduced that had successive concentra-
tions of hemolysis. The detection antibody consisted of a 
biotinylated polyclonal anti-CA-I polyclonal antibody (pur-
chased from Abeam, in a 1 : 5 ,000 dilution) and the biotin label 
was detected by a chromogenic tag. 
[0032] FIG. 1 is a graph illustrating the result of the stan-
dard curve comparing the optical density value produced by 
the chromogenic tag at 450 nanometers. FIG. 2 illustrates the 
curve that was obtained by measuring the optical density of 
plasma containing no hemolysis, followed by the concentra-
tions previously mentioned. FIG. 2 illustrates the nomogram 
principle wherein the degree of color change corresponds to 
the percentage of hemolyzed cells in a sample. It can be 
observed that the response was linear up to approximately a 
concentration of about 5% total hemolysis. Between about 5 
to 10%, a nearly horizontal asymptote was observed. 
[0033] It was determined that the equation that described 
the best fit straight line in FIG. 2 from 0 to 5% hemolysis was: 
OD~0.057(% hemolysis)+0.1 EQUATION! 
[0034] It is within the scope of the present invention that 
this equation may vary somewhat depending upon experi-
mental conditions. However, in accordance with the present 
invention, a nomogram is obtained to convert the OD reading 
into percent hemolysis using, for example, a visual aid, com-
puter or other device. For example, a sample of plasma that is 
diluted in buffer by a 1 :5 ratio yields an OD of 0.2. Solving 
equation 1 would produce a% hemolysis=((0.2-0.1)/0.057) 
*5=8.7%. 
[0035] It is also evident that the method of the present 
invention could be used to determine the percentage hemoly-
sis in the plasma fraction. The percentage of the erythrocyte 
volume that was hemolyzed could be estimated by determin-
ing the percentage hemolysis using the volume of erythro-
cytes derived from the hematocrit (Hct). The formula for 
estimating the percentage of erythrocytes hemolyzed is % 
EH=[(% hemolysis in plasma)*(l-Hct)/Hct]*100%. Thus, 
for a specimen with a 30% hematocrit and a 4% hemolysis 
measured in the plasma fraction,% EH=l00*(0.04)*(0.7)/0. 
3=9%. 
[0036] 
Blood samples 
plasma, 0% 
plasma, 0.1 % 
hemolysis 
plasma, 1% 
hemolysis 
plasma, 2.5% 
hemolysis 
plasma, 5% 
hemolysis 
plasma, 10% 
hemolysis 
plasma, 20% 
hemolysis 
Example 3 
TABLE 3-1 
OD! 
0.077 
0.062 
0.103 
0.162 
0.273 
0.398 
0.299 
ODl and OD2 are replicated values from the same sample. 
OD2 
0.071 
0.078 
0.095 
0.16 
0.279 
0.362 
0.316 
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TABLE3-2 
Protein Standard, 
ug/well OD! OD2 
0.1 0.391 0.352 
0.2 0.586 0.546 
0.4 0.746 0.694 
0.6 0.703 0.721 
0.881 0.778 
ODl and OD2 are replicated values from the same sample. 
[0037] Capturing Antybody (lst)-anti-CAI monoclonal 
Ab (Abeam) 
[0038] Detection Antybody-biotinilated anti-CAI poly-
clonal Ab (Abeam) 
[0039] Blood Samples Preparation: 
[0040] 1. Whole blood was collected from a healthy human 
into 4x3 ml vacuettes (contain 3.2% Sodium Citrate) 
[0041] 2. Plasma and RBC were separated buy centrifuga-
tion for 10 min at 2500 g. 
[0042] 3. 0.5 ml RBC were combined with 0.75 ml of 
distilled H2 0 and sonicated for 4 min in the water bath soni-
cator. 
[0043] This RBC preparation equaled 40% hemolysis. 
[0044] 4. Plasma and hemolysed RBCs were combined to 
produce the following concentrations ofhemolysis in plasma: 
0.1%, 1%, 2.5%, 5%, 10%, 20%. 
Example 4 
[0045] 
TABLE 4-1 
Blood samples OD OD OD OD average 
plasma, 0% 0.095 0.122 0.075 0.097333333 
plasma, 0.1 % 0.097 0.133 0.113 0.114333333 
hemolysis 
plasma, 0.5% 0.114 0.159 0.129 0.134 
hemolysis 
plasma, 1% 0.176 0.192 0.173 0.180333333 
hemolysis 
plasma, 2.5% 0.24 0.341 0.267 0.282666667 
hemolysis 
plasma, 5% 0.422 0.395 0.335 0.384 
hemolysis 
plasma, 10% 0.334 0.464 0.465 0.421 
hemolysis 
TABLE4-2 
Protein 
concentration, 
ng/well OD average OD OD OD 
6.25 0.014666667 0.017 O.G15 0.012 
12.5 0.032 0.044 0.025 0.027 
25 0.067666667 0.087 0.062 0.054 
50 0.14 0.159 0.157 0.104 
100 0.275 0.241 0.354 0.23 
200 0.438666667 0.463 0.493 0.36 
[0046] Capturing Antibody (lst)-anti-CA I monoclonal 
Ab (Abeam). 1:10000 dilution 
[0047] Detection Antibody-biotinilated anti-CA I poly-
clonal Ab (Abeam). 1:5000 dilution 
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[0048] Blood Samples Preparation: 
[0049] 1. Whole blood was collected from a healthy human 
into 5x3 ml vacuettes (contain 3.2% Sodium Citrate). 
[0050] 2. Plasma and RBC were separated by centrifuga-
tion for 10 minutes at 2500 g. 
[0051] 3. 0.5 ml RBC were combined with 0.75 ml of 
distilled H20 and sonicated for 4 minutes in the water bath 
sonicator. 
[0052] This RBC preparation equals 40% hemolysis. 
[0053] 4. Plasma and hemolysed RBCs were combined to 
produce the following concentrations ofhemolysis in plasma: 
0.1%, 0.5%, 1%, 2.5%, 5%, 10%. 
[0054] 5. CA I protein standard was made by preparing a 
stock of CA I (Sigma C-4396) in dH2 0 at 200 ug/ml. Further 
dilutions were made accordingly. 
[0055] FIGS. 3A and 3B illustrate the resultant standard 
curve. 
Example 5 
[0056] The following CarbonicAnhydrase I (CA-I) ELISA 
with monoclonal AB was conducted. The following materials 
were used: 
[0057] 96-well ELISA plates (Nurre 439454) 
[0058] Monoclonal capture Ab (mouse anti-CA I, Abeam, 
Inc. #70418, -20° C. in yellow box labeled "MO_CAI") 
[0059] Capture Ab dilution buffer, 0.1MNaHC03 
[0060] Refrigerator set to 4° C. 
[0061] Plate shaker in cold room set to 79 RPM 
[0062] Incubator set to 37° C. 
[0063] Wash buffer, lxPBS+0.05% Tween-20 
[0064] Blocking buffer, 1 xPBS+0.05% Tween-20+ 1 % 
BSA 
[0065] 1 xPBS 
[0066] Samples 
[0067] Standard, CA I Enzyme (Sigma C-4396; stock at 1 
mg/mL in water, -20° C.) 
[0068] Biotinylated polyclonal detector Ab (goat anti-CA I, 
Abeam, Inc. #34567, -20° C. in yellow box labeled "MO_ 
CAI") 
[0069] 
[0070] 
C.) 
Detector Ab dilution buffer, 1xPBS+1 % BSA 
streptavidin-HRP (R&D Systems cat #DY998, 4° 
[0071] Substrate, (R&D Systems cat# DY999, 4° C.) 
[0072] Stop solution (1 sulfuric acid: 4 H20, i.e. 3 ml stock 
sulfuric acid+9 ml tap H20. Invert to mix and cool down at 
-20° C. prior to use) 
[0073] The following procedure was followed: 
[0074] Capture Ab was diluted 1:10,000 in Capture Ab 
dilution buffer. 1004, was added to all wells that were used. 
Incubated overnight at 4 ° C. on a plate shaker. 
[0075] The plate was washed four times with Wash buffer, 
using a multi-channel pipette. 
[0076] 200 µL/well of Blocking buffer was added. Incu-
bated at 4° C. for 2 hours. 
[0077] Washed as in step 2. 
[0078] Samples and protein standard, 100 µL/well were 
added. Blank was PBS. Incubated at 37° C. for 90 min. 200 µL 
CA I enzyme was added to the first well of the standard row. 
100 µL PBS was added to the remaining wells that contained 
standard. Pipette 100 µL from first well and added to next well 
in the same row. Pipette used to mix and took 100 µL from that 
well and added to the next. Repeated down the row to make 
serial dilutions of the CA I standard; prepared dilutions fresh 
each time. 
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[0079] Washed as in step 2. 
[0080] Detector Ab was diluted 1:5,000 (1:2,500 when 
stored 1: 1 in glycerol) in Detector Ab dilution buffer. 100 
µL/well added. Incubated for 1 hour at 4 ° C. on a plate shaker. 
[0081] Washed as in step 2. 
[0082] Diluted streptavidin-HRP 1 :200 in Blocking buffer. 
Added 100 µL/well. Incubated at 4° C. for 30 minutes. 
[0083] Washed as in step 2. 
[0084] Washed 3 times with lxPBS. 
[0085] Removed substrate from 4 ° C. and warmed to room 
temperature. Made a 1: 1 dilution of reagent A and reagent B. 
Added 100 µL/well. Incubated 30 min at room temperature. 
Stopped reaction with 50 µL/well of stop solution. Reaction 
turned yellow. Read at 450 nm. 
[0086] Note that the plate was protected from light by wrap-
ping in foil while incubating. 
[0087] The following results were obtained following the 
above procedure. 
TABLE 5-1 
Standard concentration (ug/mL) 
100 90 80 70 60 50 40 30 
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greater than ( 4.1+(2.8x2)) or greater than about 10 ug/mL is 
abnormally high at the 95 percentile. It was also concluded 
that an OD of about 0.25 to 0.30 indicated a CA I concentra-
tion of about 10 ug/mL or higher. Thus, OD values of about 
0.2 to 0.3 corresponded to the lower limit range that signifies 
a clinically significant level of intravascular hemolysis. Opti-
cal density values above 0.3 indicated worsened burden of 
hemolysis and indicated a clinically significant level of 
hemolysis. Optical density values below 0.2 indicated less 
hemolysis and indicated a clinically insignificant level of 
hemolysis. 
[0090] It will therefore be readily understood by those per-
sons skilled in the art that the present invention is susceptible 
of broad utility and application. Many embodiments and 
adaptations of the present invention other than those herein 
described, as well as many variations, modifications and 
equivalent arrangements, will be apparent from or reasonably 
suggested by the present invention and the foregoing descrip-
10 
Standard curve 0.999 1.072 1.059 1.196 0.995 0.869 0.661 0.652 0.474 0.279 0.185 0.032 
TABLE 5-2 
Concentration 
Biosite Plasma Sample# OD (ug/mL) 
0.336 14.18 
9 0.067 2.09 
10 0.203 7.28 
11 0.108 2.92 
12 0.067 2.09 
13 0.093 2.51 
14 0.123 3.32 
15 0.134 3.62 
16 0.133 3.59 
17 0.137 3.7 
18 0.165 4.46 
19 0.099 3.09 
20 0.111 
21 0.132 3.58 
22 0.051 1.59 
23 0.058 1.81 
24 0.173 4.68 
25 0.114 3.08 
26 0.273 9.78 
27 0.127 3.43 
28 0.087 2.72 
29 0.160 4.32 
[0088] FIGS. 3A and 3B demonstrate plots of two sets of 
data, one being a standard curve using commercially obtained 
CA-I (represented by the closed diamonds, in both plots 3A 
and 3B). FIG. 3A shows the linearity across a wide concen-
tration of CA-I. FIG. 3B shows the standard curve at a clini-
cally significant CA-I concentration range, (plotted with 
closed diamonds) and the line representing the best fit straight 
line. All other symbols representing the measured CA-I val-
ues from plasma samples from 22 humans. These data corre-
spond to Tables 5-1and5-2. 
[0089] The mean was 4.1291 and the standard deviation 
(SD) was 2.8882. It was concluded from this data that a value 
ti on thereof, without departing from the substance or scope of 
the present invention. Accordingly, while the present inven-
tion has been described herein in detail in relation to its 
preferred embodiment, it is to be understood that this disclo-
sure is only illustrative and exemplary of the present invention 
and is made merely for purposes of providing a full and 
enabling disclosure of the invention. The foregoing disclo-
sure is not intended or to be construed to limit the present 
invention or otherwise to exclude any such other embodi-
ments, adaptations, variations, modifications and equivalent 
arrangements. 
What is claimed is: 
1. A method for detecting hemolysis m a subject, the 
method comprising: 
correlating optical density of a plasma component of a 
blood sample with carbonic anhydrase concentration to 
determine a percentage hemolysis present in the plasma 
component of the blood sample. 
2. The method according to claim 1, wherein correlating 
comprises plotting the optical density on a nomogram. 
3. The method according to claim 1, wherein correlating 
comprises calculating the optical density using an equation to 
estimate the percentage hemolysis present in the plasma com-
ponent. 
4. The method according to claim 3, wherein the calcula-
tion is automated using a computer or other device to run a 
computerized analysis. 
5. The method according to claim 1, wherein the carbonic 
anhydrase concentration is of carbonic anhydrase I or car-
bonic anhydrase II. 
6. The method according to claim 1, wherein concentration 
is determined by analysis of spectra produced by bombarding 
a portion of the plasma with a beam of electrons. 
7. A method for detecting hemolysis in a subject, the 
method comprising: 
assaying a plasma component separated from a blood 
sample obtained from a subject, and 
US 2011/0124019 Al 
correlating optical density of the plasma component of the 
blood sample with carbonic anhydrase I concentration to 
determine a percentage hemolysis present in the plasma 
component of the blood sample. 
8. The method according to claim 7, wherein the assay 
results in a color change that can be optically measured. 
9. The method according to claim 7, wherein the plasma 
component is assayed by performing an enzyme-linked 
immunosorbent assay (ELISA) involving at least one anti-
body derived from a monoclonal cell line with a Fab portion 
that specifically recognizes an amino acid sequence unique to 
carbonic anhydrase I. 
10. The method according to claim 9, wherein the antibody 
comprises a biotin label. 
11. The method according to claim 9, wherein a fluores-
cent, colorimeter or chemical property is present in the assay. 
12. The method according to claim 7, wherein the optical 
density of the plasma component of the blood sample is 
determined at a specified wavelength. 
13. The method according to claim 7, wherein the optical 
density in a range of about 0.2 to 0.3 represents a range where 
the degree of hemolysis becomes clinically significant for 
diagnosis and treatment of the subject. 
14. The method according to claim 7, wherein an optical 
density less than 0.2 indicates a clinically insignificant level 
ofhemolysis. 
15. The method according to claim 7, wherein an optical 
density greater than 0.3 indicates a clinically significant level 
ofhemolysis. 
16. A method for optimizing therapeutic efficacy associ-
ated with treatment of hemolysis in a subject, the method 
comprising: 
determining a percentage of hemolysis in a plasma com-
ponent separated from a blood sample obtained from a 
subject by correlating optical density of the plasma com-
ponent of the blood sample with carbonic anhydrase I 
activity, 
wherein the determined percentage ofhemolysis is used to 
optimize the therapeutic efficacy associated with treat-
ment ofhemolysis in a subject. 
17. A test forthe detection ofhemolysis in a subject, the test 
comprising: 
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a nomogram comprising a first set of data corresponding to 
optical density of a plasma component of a blood sample 
obtained from a subject and a second set of data corre-
sponding to carbonic anhydrase I activity, wherein the 
first set of data and the second set of data are plotted to 
form a graphical measure or an equation used to deter-
mine the percentage ofhemolysis in the sample. 
18. The test according to claim 17, wherein the nomogram 
detects hemolysis up to about at least 5% to 6%. 
19. A method for optimizing therapeutic efficacy associ-
ated with treatment of hemolysis in a subject, the method 
comprising: 
obtaining a percentage of hemolysis from a nomogram 
comprising a first set of data corresponding to optical 
density of a plasma component of a blood sample 
obtained from a subject and a second set of data corre-
sponding to carbonic anhydrase I activity, wherein the 
first set of data and the second set of data are plotted to 
form a graphical measure or an equation used to deter-
mine the percentage ofhemolysis in the sample, 
quantifying the percentage hemolysis based upon mea-
surement ofhematocrit, and 
using a formula to estimate a percentage of erythrocytes 
hemolyzed in-vivo. 
20. A method of diagnosing or treating a patient, the 
method comprising: 
obtaining a percentage of hemolysis from a nomogram 
comprising a first set of data corresponding to optical 
density of a plasma component of a blood sample 
obtained from a subject and a second set of data corre-
sponding to carbonic anhydrase I activity, wherein the 
first set of data and the second set of data are plotted to 
form a graphical measure or an equation used to deter-
mine the percentage ofhemolysis in the sample, and 
using the obtained percentage ofhemolysis to diagnose or 
treat the patient. 
21. The method according to claim 20, wherein for treat-
ment by dosage of medication, a value of 0% hemolysis 
indicates a zero dosage amount, a value of above 5% hemoly-
sis indicates full dosage, and a value between 0 and 5% 
hemolysis indicates partial dosage, determined in proportion 
to the percentage ofhemolysis obtained. 
* * * * * 
